• 20 hours Lithium Hype Can't Live Up To Supply Realities
  • 23 hours Tesla Scrambles To Salvage Its Stumbling Solar Business
  • 2 days Why Silicon Valley Is Moving To Toronto
  • 2 days Hong Kong Residents Are Fleeing To Taiwan At A Record Pace
  • 2 days Trickle Down Tax Cuts Aren't Helping Bolster GDP Growth
  • 3 days Wealth Gap Widens Between Baby Boomers And Millennials
  • 3 days How Investors Are Playing Uncertain Markets
  • 3 days Demand For Cash Is On The Rise
  • 3 days The Best Way To Ride The Gold Rally
  • 4 days Corn Industry Reeling After Shocking Ethanol Decision
  • 5 days Gold Miners Eye Further Upside
  • 5 days Alibaba Exec Sets Record With $3.5 Billion Brooklyn Nets Purchase
  • 6 days Smart Contracts: The Tech Reshaping Entire Industries
  • 6 days Protests Threaten $5 Billion Peruvian Copper Mine
  • 7 days Why Wealthy Kids Are Getting Into College For Free
  • 7 days Is Is Too Late To Get Into The New Gold Boom?
  • 7 days Solar Tech Breakthroughs Spark Surge In Adoption
  • 8 days These Rare Stones Are About To Become Priceless
  • 8 days Why Silver Miners Aren’t Living Up To Expectations
  • 8 days WeWork Reveals Huge Losses Ahead Of IPO
Michael Kern

Michael Kern

CONIL

Michael Kern is a newswriter and editor at conil.me, Oilprice.com, and a writer at Macro-Investing.com.  

Contact Author

  1. Home
  2. Investing
  3. Other

Three Cannabis Trends Flying Under Investors’ Radars

Marijuana

It doesn't seem that long ago when cannabis was seen merely as the feel-good drug of choice for kids aiming to blow off steam. But over time, after countless studies on the plant, its benefits became too hard to ignore.

Today, cannabis is utilized not just to blow off steam, but to treat a number of diseases which effect the body immune system, pain and inflammation, seizures and even mental disorders.

Cannabis is finally being recognized across the world as a practical alternative to costly, ineffective and in some cases unsafe medications.

And thanks to this, not only are a great deal of people getting the medical care they really need, an entire industry is growing right in front of our eyes.

These realizations have led to a surge in marijuana usage across the United States and Canada over the past 10 years. Throughout all age groups and demographics.

And while it is already legal, and blossoming, in Canada, the push to bring marijuana into broader markets in the United States is gaining traction. In a big way.

Even in the most socially conservative states in America, the genuine wunderdrug is being legalized.

Take Oklahoma, for instance. Medical cannabis was legalized in the state just last year, and already, state regulators are swamped with licensing applications and medical card requests. And that's only half the story.

Recreational cannabis is also catching fire throughout the country. Many states in the East Coast are already in the process of raising policies to accommodate the frustrating demand of their constituents.

And as the most densely inhabited region in the country, that suggests already-established marijuana companies are simply waiting on consent prior to the next 'green rush' starts.

But legalization – both medical and recreational – is the most obvious trend in this emerging market. Cannabis is a fast-moving market. New tech, new products, new regulations and new consumers are sprouting up every day.

And because of this, it’s a very lucrative space for early investors who can identify these emerging trends.

Here are the three most important emerging trends in the cannabis market today (and the companies leading the charge):

The CBD Health and Wellness Explosion

Most people know what THC is, or at least how it impacts people. It’s the compound in cannabis that leaves users feeling giddy, goofy, and, well, stoned. Think Snoop Dogg or Cheech and Chong. But that’s not the end of the story for cannabis.

In recent years, researchers have perfected the art of extracting another compound – CBD (cannabidiol).

Why?

Because it offers all of the amazing medical benefits associated with cannabis, without the glassy eyes and uncontrollable bursts of laughter. And consumers can’t get enough of it.

From migraines to depression, as the legal floodgates open, consumers are buying up every new product hits the market. And smart cannabis companies are happy to help.

One of the companies leading this charge is Supreme Cannabis. Supreme is looking at the world stage as this new market develops. With a global vision and the drive to pursue this opportunity, Supreme is already carving out its market share in key regions as new regulation is passed.

Recently, the company launched its UK-based investment arm Supreme Heights, a platform created for the sole purpose of identifying and capitalizing on opportunities in the UK and Europe’s CBD health and wellness market.

Navdeep Dhaliwal, CEO of Supreme Cannabis explained, “The rapidly evolving CBD markets in the UK and Europe present compelling investment opportunities given the promising environments for new health and wellness companies to establish differentiated brands and capture meaningful market share.”

But other companies, like Auxly Cannabis, are taking a slightly different – more local - approach. As a veteran in the Canadian market, Auxly has positioned itself ahead of the competition in the coming U.S. market boom thanks to its ambitious wheeling and dealing across Canada. With ample supply, a strong distribution platform, extraction tech and regulatory knowledge, Auxly is ready to pounce.

And Auxly’s expansion isn’t slowing anytime soon. Recently, the company even secured cultivation and processing licenses at a new 27,700 square-foot facility. The new venture is said to focus on premium strains, offering nothing but the best products.

Hugo Alves, President of Auxly explained, “This is a big milestone for one of our key subsidiaries and member of the Auxly family. We know that Andrew and his team are going to produce some of the best cannabis flower available in Canada and we can’t wait to share it with Canadian consumers.”

Big Data and Supply Chain Management

What’s the genius of Amazon?

Simple: control of information.

Jeff Bezos turned a little online book store into one of the world’s most valuable corporate behemoths by applying technological solutions to complex problems—creating a model mirrored around the world.

Now, a little-known company is trying to duplicate that feat. TruTrace Technologies is helping other companies “Amazonify” their businesses— creating a niche in the tech world that has yet to be filled. In other words, it has no competitors yet.

As any retail firm knows, distribution is essential—it can be the biggest source of additional costs and the perfect place to improve efficiency.

Inefficiency can be a killer—a study from 2012 showed that distribution centers lose 3000 hours a year to unproductive workflow. Lack of control over information costs even more—large businesses lost $47 million per year to inefficiencies in data transfer.

That’s where TruTrace Technologies comes in. The company has developed a unique platform to help companies cut costs, streamline marketing and distribution procedures, and eliminate inefficiency in the supply chain.

It’s all about finding the best tech to fit the problem—and TruTrace Technologies has built a sturdy platform that covers an entire industry’s supply chain, from top to bottom. Plus, the company’s working in an exciting, rapidly growing new industry—cannabis.

TruTrace Technologies is breaking into cannabis, but it’s got the potential to take on much bigger markets—including retail groceries, which is currently dominated by big supermarket chains like Kroger Company ($105 billion) and H.E.B. ($21 billion).

And where other cannabis plays have focused on production—which firms have the most product, the lowest prices, the biggest chunk of market—TruTrace hopes to make a splash by tackling the issues surrounding the emergence of a new market—one that could be worth billions of dollars.

For TruTrace, the possibilities for growth are extremely attractive. They already have the attention of the large medical community in the Canadian market-place and some in the US market-place.

Joint Ventures and M&As

Currently, corporate tie-ups are all the rage in the marijuana sector. Mostly it’s been big pot and big tobacco buying marijuana companies in multi-billion-dollar deals in the hope of getting a piece of the action.

  • Constellation Brands invested $4 billion investment into Canopy Growth Corporation
  • Altria Group Inc. has agreed to take a $1.8B minority stake in Cronos Group Inc.
  • Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc. for C$1.1 billion ($852 million.

And while big-name brands get all of the attention, other smaller companies, like Emerald Health Therapuetics are flying under the radar. As a veteran in the cannabis sector, Emerald has placed a lot of emphasis on its strategic partnerships and acquisitions.  With a highly experienced team in life sciences and product development, the company is truly carving out a name for itself.

Emerald’s reach expands through virtually every sub-sector of the cannabis industry, including cultivation, product development, research, and pharmaceutical solutions. But one of its most unique qualities is that it does not limit itself to pure-cannabis deals.

Emerald recently launched a new product line aiming to support the endocannabinoid system to help maintain equilibrium in the body. Dr. Gaetano Morello, Naturopathic Doctor, CEO of Emerald Health Naturals explained, “The Endo product line was developed by leading naturopathic doctors who previously launched new products into the natural health market, and we are pleased to now introduce Canadian consumers and retailers to this new nutritional supplement as an alternative to existing drugs, supplements, and cannabis.”

Another cannabis giant in the M&A push is Hexo. The company, which is engaged in the production, distribution and marketing of cannabis and cannabis products, made headlines after it secured a huge deal with international beverage giant Molson Coors. The joint venture marked a new era in recreational marijuana, bringing two heavyweight industries together under one roof.

HEXO’s CEO and co-founder Sebastien St-Louis, explained, “As two leading companies who share a track record of excellent practices, as well as respect for law and regulations, HEXO and Molson Coors Canada have established a relationship built on trust, and together we will develop responsible, high-quality cannabis-infused beverages for the consumable cannabis market in Canada.”

While most of the major pot-stock news comes from Canada, one of the industry’s top wheelers and dealers actually comes from California. MedMen Enterprises is quietly gaining traction in the U.S. market, largely thanks to its strategic acquisitions and focus on expanding its domestic footprint.

In just a year, MedMen has closed on two major deals, including its buyout of California-bases retailer One Love and its acquisition of medical-marijuana provider PharmaCann.  The PharmaCann deal, in particular, solidified MedMen’s position as an ‘up-and-comer- to watch. The $682 million acquisition made headlines as the largest marijuana deal at the time, with many analysts praising it as a major steal for MedMen.

By Michael Kern for conil.me 

IMPORTANT NOTICE AND DISCLAIMER

PAID ADVERTISEMENT. This communication should be viewed as a paid advertisement. Leacap Ltd and CONIL and their owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher was not specifically paid for this communication.  However, a related company was previously compensated by TruTrace Technologies In May 2018, to produce and disseminate other similar articles and certain banner ads. This compensation should be viewed as a major conflict with our ability to be unbiased.

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP. The owner of CONIL owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The owner of CONIL has no present intention to sell any of the issuer’s securities in the near future but does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The owner of CONIL will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies, the success of the companies’ technology, the size and growth of the market for the companies’ products and services, the companies’ ability to fund their capital requirements in the near term and long term, pricing pressures, etc. 

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here http://CONIL/terms-and-conditions If you do not agree to the Terms of Use http://CONIL/terms-and-conditions, please contact CONIL to discontinue receiving future communications.

INTELLECTUAL PROPERTY. CONIL is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

Back to homepage

Leave a comment

Leave a comment